CN114728088A - 稳定的浓缩的放射性药物组合物 - Google Patents

稳定的浓缩的放射性药物组合物 Download PDF

Info

Publication number
CN114728088A
CN114728088A CN202080079709.9A CN202080079709A CN114728088A CN 114728088 A CN114728088 A CN 114728088A CN 202080079709 A CN202080079709 A CN 202080079709A CN 114728088 A CN114728088 A CN 114728088A
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
acid
ascorbic acid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080079709.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·F·马里亚尼
F·奥兰迪
L·富加扎
L·萨切蒂
M·特德斯科
D·巴巴托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN114728088A publication Critical patent/CN114728088A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080079709.9A 2019-09-16 2020-09-15 稳定的浓缩的放射性药物组合物 Pending CN114728088A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16
PCT/EP2020/075767 WO2021052960A1 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Publications (1)

Publication Number Publication Date
CN114728088A true CN114728088A (zh) 2022-07-08

Family

ID=67981980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080079709.9A Pending CN114728088A (zh) 2019-09-16 2020-09-15 稳定的浓缩的放射性药物组合物

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20150265732A1 (en) * 2012-09-25 2015-09-24 Biosynthema Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20150265732A1 (en) * 2012-09-25 2015-09-24 Biosynthema Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途

Also Published As

Publication number Publication date
AR119974A1 (es) 2022-01-26
EP4031193A1 (en) 2022-07-27
WO2021052960A1 (en) 2021-03-25
US20220401593A1 (en) 2022-12-22
JP2022548875A (ja) 2022-11-22
IL291315A (en) 2022-05-01
KR20220063218A (ko) 2022-05-17
TW202123976A (zh) 2021-07-01
US20250332301A1 (en) 2025-10-30
JP2026031934A (ja) 2026-02-25
AU2020349002A1 (en) 2022-04-28
JP7762648B2 (ja) 2025-10-30
AU2020349002B2 (en) 2024-05-02
CA3154302A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CN114728088A (zh) 稳定的浓缩的放射性药物组合物
CN114728087B (zh) 放射性标记grpr拮抗剂的方法及其试剂盒
TW387898B (en) Somastotatin analogs containing chelating groups and their radiolabeled compositions
JP2021506784A (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
CN118647415A (zh) 包含225锕标记的络合物和铋多价螯合剂的药物组合物
CN117159753A (zh) 放射性标记的伊文思蓝衍生物药物的制备方法及用途
JP2024045147A (ja) 放射性医薬品用のソマトスタチンアナログを含む組成物
CA3103190A1 (en) Composition containing a somatostatin analogue for radiopharmaceutical use
CN118119581A (zh) 放射性药物、其生产方法以及在疾病治疗、诊断和成像中的用途
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
WO2023202730A2 (zh) 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途
CN113195005B (zh) 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
CN114796532A (zh) 放射性标记的伊文思蓝衍生物药物水溶液及其用途
RU2855011C1 (ru) Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination